Insmed (NASDAQ:INSM) Sets New 12-Month High - Should You Buy?

Key Points

• Insmed's shares reached a new 52-week high at $162.44, reflecting a significant increase from the previous close of $158.28.
• The company reported a quarterly loss of ($1.70) EPS, missing estimates by ($0.40), despite revenues of $107.42 million which exceeded expectations.
• Analysts maintain a consensus rating of "Moderate Buy" for Insmed, with a projected price target of $149.06.

Shares of Insmed, Inc. (NASDAQ:INSM - Get Free Report) reached a new 52-week high on Wednesday . The stock traded as high as $162.44 and last traded at $162.32, with a volume of 1627363 shares traded. The stock had previously closed at $158.28.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. William Blair assumed coverage on Insmed in a research report on Wednesday, August 20th. They set an "outperform" rating for the company. Mizuho upped their price objective on Insmed from $130.00 to $165.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 13th. Bank of America upped their price objective on Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a research report on Wednesday, June 11th. Truist Financial increased their price target on Insmed from $126.00 to $139.00 and gave the company a "buy" rating in a research report on Thursday, August 14th. Finally, Royal Bank Of Canada increased their price target on Insmed from $108.00 to $120.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. Nineteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $149.06.

Insmed Stock Up 2.6%

The firm has a 50-day moving average of $134.74 and a 200 day moving average of $100.23. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The stock has a market capitalization of $34.31 billion, a price-to-earnings ratio of -28.43 and a beta of 1.03.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. During the same period in the previous year, the business earned ($1.94) earnings per share. The business's quarterly revenue was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Roger Adsett sold 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $127.58, for a total value of $3,189,500.00. Following the completion of the sale, the chief operating officer directly owned 105,637 shares of the company's stock, valued at $13,477,168.46. This trade represents a 19.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Melvin Md Sharoky sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $145.39, for a total value of $1,453,900.00. Following the completion of the sale, the director directly owned 262,675 shares of the company's stock, valued at approximately $38,190,318.25. The trade was a 3.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 219,568 shares of company stock valued at $28,305,070. Insiders own 3.00% of the company's stock.

Hedge Funds Weigh In On Insmed

A number of large investors have recently made changes to their positions in INSM. Wealth Enhancement Advisory Services LLC increased its stake in shares of Insmed by 10.5% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 3,231 shares of the biopharmaceutical company's stock worth $223,000 after purchasing an additional 307 shares during the period. NBC Securities Inc. bought a new position in shares of Insmed during the first quarter worth approximately $49,000. Park Avenue Securities LLC increased its stake in shares of Insmed by 38.7% during the first quarter. Park Avenue Securities LLC now owns 11,036 shares of the biopharmaceutical company's stock worth $842,000 after purchasing an additional 3,081 shares during the period. Harbor Capital Advisors Inc. increased its stake in shares of Insmed by 22.2% during the first quarter. Harbor Capital Advisors Inc. now owns 72,816 shares of the biopharmaceutical company's stock worth $5,555,000 after purchasing an additional 13,216 shares during the period. Finally, GAMMA Investing LLC increased its stake in shares of Insmed by 62.0% during the first quarter. GAMMA Investing LLC now owns 1,009 shares of the biopharmaceutical company's stock worth $77,000 after purchasing an additional 386 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.